Abstracts treated with healthy subjects MPs did not affect Á ow-induced dilation, these vessels showed a reduced prostacyclin-component that was completely compensated by the NO-component of the response. The endothelial dysfunction induced by MPs from OSAS was caused by the reduction of both NO-and prostacyclin-but not the endothelium-derived hyperpolarizing factor-components of the response in SMA. These data provide evidence that circulating MPs from OSAS patients inÁ uence both endothelial function and vascular reactivity. During cell activation or apoptosis, cells release vesicles, also called microparticles (MPs) from the plasma membrane. Since composition of MPs is dependent on cell origin and the type of stimulation, we compared the effects of MPs generated from both apoptotic T lymphocytes and apoptotic monocytes on endothelial function with respect to both nitric oxide (NO) pathway and reactive oxygen species (ROS). MPs were produced by treatment of either human T lymphocytes with the apoptotic agent actinomycin D or human monocytic cell line THP-1 with the apoptotic agent, the etoposide VP-16. Human Eahy 926 endothelial cells were incubated with 10 õg/ml MPs for 24h. Apoptotic MPs from human T lymphocytes decreased NO production that was associated with overexpression and phosphorylation of endothelial NOsynthase (eNOS). Also, T lymphocytes MPs enhanced expression of caveolin-1 and decreased its phosphorylation. T lymphocytes MPs enhanced ROS by a mechanism sensitive to xanthine oxidase and P-IkappaBalpha inhibitors. PI3-kinase inhibition reduced the effects of T lymphocytes MPs on eNOS, but not on caveolin-1, whereas it enhanced the effects of MPs on ROS production. Inhibition of MEK reversed eNOS phosphorylation but it had no effect on ROS production induced by T lymphocytes MPs. By contrast, apoptotic MPs from human monocytes increased both NO production and in much less extent ROS. These effects were associated with a decrease of caveolin-1 expression and increased its phosphorylation, without affecting eNOS expression and phosphorylation. The inhibitor of the PI-3kinase, LY294002, reversed the effects of monocyte MPs on caveolin-1 expression but not on its phosphorylation. The MEK1/2 inhibitor, U0126, reversed the decrease of caveolin-1 expression induced by MPs from monocytes. Interestingly, U0126 potentiated ROS production induced by monocyte MPs. Whereas in vivo injection of T lymphocytes MPs in mice impaired endothelial function, apoptotic MPs from human monocytes did not affect endothelium-dependent relaxation. In addition, monocyte MPs were able to promote in vitro angiogenesis. In summary, these results highlight differential effects of apoptotic MPs from different origins by activating diverse multiple pathways related to NO and ROS productions.
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DIFFERENTIAL EFFECTS OF MICROPARTICLES FROM HUMAN APOPTOTIC T LYMPHOCYTES AND FROM HUMAN APOPTOTIC MONOCYTES IN ENDOTHELIAL CELLS
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STUDY ON THE MECHANISM OF HUMAN TELOMERASE ASSEMBLY
For further analysis on the role of the SMN complex in telomerase assembly, we tested by yeast two hybrid assays whether other proteins of this complex can interact with H/ACA RNP proteins and their assembly factors. We discovered a possible interaction between NAF1, Gemin 3 and Gemin8. Hence, the SMN complex may be involved in the replacement of NAF1 by GAR1 : it may associate with GAR1 through an interaction with SMN, and with the pre-H/ ACA RNP complex through interaction of NAF1 with Gemin3 and 8, allowing the replacement of NAF1 by GAR1. We are testing this hypothesis. The SMN complex may also be involved in hTERT binding to the 5' domain of hTR and we will also explore this possibility.
Through these studies we should bring insight into telomerase assembly that may be useful to understand telomere attrition in cardiovascular diseases. Contexte -Les MP sont générées par le remaniement de la membrane plasmique suite à l'activation des cellules sanguines ou des cellules endothéliales.
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CARACTERISATION DES MICROPARTICULES CIRCULANTES CHEZ LES PATIENTS ATTEINTS DU SYNDROME DES ANTICORPS ANTI-PHOSPHOLIPIDES
Objectif -Nous avons caractérisé les microparticules circulantes chez les patients atteints du syndrome des anticorps antiphospholipides (SAPL), thrombophilie acquise caractérisée par un risque augmenté de thromboses et de complications obstétricales.
Les anticorps anti-phospholipides (APL) jouent un rôle majeur dans ces manifestations, impliquant probablement une altération de la fonction endothéliale ce qui induit un état prothrombotique, venant ampliÀ er les effets procoagulants sur les plaquettes.
Méthodes -Nous avons quantiÀ é les MP dans le plasma et déterminé leur origine cellulaire par la cytométrie en Á ux. Le plasma dépourvu en plaquette (PDP) a été préparé, selon les recommandations de la société internationale de thrombose et d'hémostase. Grâce à des billes calibrées en taille, nous avons délimité une fenêtre d'analyse des évènements de taille de 0.5 à 1,5 õm, marquées par les anticorps spéciÀ ques anti-CD41 et anti-CD31 (double marquage) pour identiÀ er les MP plaquettaires, anti-CD45 pour les MP leucocytaires, anti-CD235a pour les MP érythrocytaires et anti-CD144 pour les MP endothéliales. L'utilisation de billes Á uorescentes en quantité connue nous a permis de les quantiÀ er.
Résultats -23 patients SAPL ont été inclus selon les critères de classiÀ cation actualisés à la conférence internationale de Sydney, publiés en 2006, à savoir l'association d'au moins un évènement clinique (thromboses artérielles et/ou veineuses, manifestations obstétricales) et présence d'APL. Nous avons observé chez le groupe de patients SAPL en comparaison au groupe de sujets témoins (24 sujets) une augmentation signiÀ cative du nombre de MP plaquettaire (1.7 fois, p < 0.029), endothéliale (1.7 fois, p < 0.04), leucocytaire (1.6 fois, p < 0.03) et érythrocytaire (1,4 fois, p < 0.016).
Conclusions -Nos résultats montrent des niveaux élevés de microparticules circulantes chez les patients atteints de SAPL suggérant une augmentation de l'activation cellulaire probablement associée aux évènements cliniques. Nous incluons actuellement un deuxième groupe de patients présentant des signes biologiques (la présence d'APL) sans thromboses ni manifestations obstétricales pour comparer le niveau et/ou l'origine des MP chez les patients symptomatiques et asymptomatiques. Among the proposed hypothesis for inÁ ammatory bowel disease (IBD) pathogenesis, a vascular cause has been suggested, mostly in reference to anatomic and pathological studies. We previously reported in small mesenteric arteries from Crohn's disease patients a balance between vasoconstrictor products from cyclooxygenase and unidentiÀ ed vasodilatory products that maintained vascular reactivity in a physiological range despite an increase of circulatory cytokines in these patients (Tabernero et al., Circulation, 2003) . Microparticles (MPs) are membrane vesicles released during cell activation and apoptosis. Elevated levels of circulating MPs have been detected in pathologic conditions and their increase has been associated with disease activity and/or prognosis. We investigated whether MPs from IBD patients may play a role in the regulation of endothelial function and vascular reactivity in this disease. Blood samples were obtained either from IBD patients as well as age and sex-matched healthy subjects. MPs concentration and origin were assessed by Á ow cytometry using speciÀ c antibodies. Male Swiss mice were injected intravenously with MPs from IBD patients or with saline solution and sacriÀ ed after 24 hours. Endothelial function and vascular reactivity were studied on aortic rings and small mesenteric resistance arteries (SMA) by myography and arteriography, respectively. Patients with IBD displayed increased circulating levels of MPs compared to healthy subjects including those from procoagulant, platelet and activated platelet, endothelial, leukocyte and erythrocyte origins. In aorta, MPs from IBD patients compared to saline signiÀ cantly reduced both endothelium-dependent relaxation to acetylcholine and contraction to serotonin. In SMA, although MPs from IBD patients did not affect Á ow-induced dilation, a reduced NO-component that was completely compensated by the endothelium-derived hyperpolarizing factor-component of the response was highlighted. Besides, MPs from IBD did not affect myogenic tone in SMA. These results provide further evidence of increased circulating levels of MPs in patients with IBD. MPs origin may play a role in enhanced coagulation and inÁ ammatory states reported in IBD patients. Finally, MPs from IBD patients inÁ uence both endothelial dysfunction and vascular hyporeactivity in the experimental model used. Dietary supplements in polyunsaturated fatty acids (PUFA), particularly omega-3, are well known for the beneÀ cial role that they play in preventing cardiovascular diseases. The aim of this study was to determine the role of PUFA on the modulation of apoptosis induced by hypochlorous acid oxidized LDL (HOCl-oxLDL) in U937 monocytic cell lines, and the impact on atherosclerosis in Apolipropotein E-knockout (ApoE-/-) mice.
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INCREASE IN CIRCULATING MICROPARTICLES IN INFLAMMATORY BOWEL DISEASE PATIENTS INDUCES VASCULAR ALTERATIONS
(Partially supported by Ferring France Laboratories).
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MONOCYTE APOPTOSIS IS MODULATED BY POLYUNSATURATED FATTY ACIDS TREATMENT
We tested the potential effect on modulation of HOCl-oxLDLinduced apoptosis after a cellular membrane overloading with eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (ARA) or oleic acid (OA). We showed that both EPA and ARA, exerted a pro-apoptotic effect through a speciÀ c activation of the intrinsic mitochondrial apoptotic pathway including an increase in DNA fragmentation, a speciÀ c activation of caspase activity and protein expression and a loss of mitochondrial membrane potential. In parallel, three groups of ApoE-/-mice were fed on diet supplemented with EPA, or DHA, or not, for 5-or 12-weeks. Whatever the treatment, serum cholesterol concentrations were similar in the three groups and PUFA supplementation do not appeared to prevent development of atherosclerotic plaques measured by oil red O-staining of descending aorta or aortic sinus.
These data demonstrate a novel function of dietary supplements in PUFA with likely consequences in apoptosis in cultured monocytes, with no protection against atherosclerosis development in ApoE-/-mice.
